MannKind generated 111955000 in total revenue in Q4 2025, up 46% year-over-year, driven by contributions from Furoscix, Afrezza growth, and higher royalties and collaborations revenue. The company reported a net loss of 15948000 and an operating loss of 7687000 for the quarter.

MannKind posted Q3 2025 revenues of $82.1 million, a 17% increase from the prior year, driven by growth in royalties, Afrezza sales, and collaborations. GAAP net income declined slightly, while non-GAAP net income rose significantly.

MannKind Corporation delivered a strong second quarter in 2025, with total revenues increasing by 6% year-over-year to $76.5 million. The company achieved net income of $0.7 million, a significant improvement from a net loss in the prior year, and reported non-GAAP net income of $13.9 million. Key drivers included higher royalties from Tyvaso DPI and increased Afrezza sales due to higher demand and price. The company also made significant progress in its pipeline, submitting an sBLA for Afrezza in pediatric patients and advancing its MNKD-101 and MNKD-201 programs.

MannKind Corporation reported strong financial results for the first quarter of 2025, with significant increases in total revenue, net income, and non-GAAP net income compared to the same period in the prior year. The company also made progress on key pipeline programs, including Afrezza for pediatric patients and MNKD-101.

MannKind Corporation delivered robust financial results in the fourth quarter of 2024, with total revenues increasing by 31% year-over-year to $76.776 million and net income reaching $7.422 million, a significant improvement from the previous year. The company also reported a non-GAAP net income of $22.952 million.

MannKind Corporation reported a 37% increase in total revenues for Q3 2024 compared to Q3 2023, reaching $70 million. The growth was primarily driven by increased royalties from Tyvaso DPI and higher collaboration and services revenue. The company also made significant progress in its clinical development programs, including the Phase 3 trial of MNKD-101 and the successful completion of the Phase 1 trial of MNKD-201.

MannKind Corporation reported total revenues of $72 million for Q2 2024, a 49% increase compared to Q2 2023. The company is approaching an annual revenue run rate of over $275 million based on the first half of 2024.

MannKind Corporation reported a strong first quarter in 2024, marked by a 63% increase in total revenues to $66 million and a net income of $11 million. The company also highlighted clinical development progress, including FDA Fast Track designation and IND clearance for MNKD-101.

MannKind Corporation reported a strong fourth quarter in 2023, with total revenues of $58 million, a 62% increase compared to 2022. The company's net income was $1 million, with a non-GAAP net income of $7 million. MannKind ended the year with a robust cash position of over $300 million, positioning it well for upcoming clinical data read-outs and the advancement of its MNKD-101 and MNKD-201 programs.

MannKind Corporation reported a strong third quarter in 2023, with total revenues of $51 million, a 56% increase compared to Q3 2022. Net income was $2 million, and non-GAAP net income reached $4 million. The company's growth was primarily driven by Tyvaso DPI royalties and increased Afrezza sales.

MannKind Corporation reported a significant increase in total revenues for Q2 2023, driven by growth in Tyvaso DPI royalties and Afrezza net revenues, along with revenues from collaborations and services. The company achieved positive income from operations during the quarter.

MannKind Corporation reported a strong first quarter in 2023, with total revenues of $41 million, a 239% increase compared to Q1 2022, driven by strong demand for Tyvaso DPI which contributed $23 million in revenues.

MannKind Corporation reported a total revenue of $36.059 million for Q4 2022, a 188% increase compared to Q4 2021. The growth was driven by increased Afrezza net revenue, V-Go acquisition, higher collaborations and services revenue, and royalties from Tyvaso DPI. The company is focusing on advancing its product pipeline, including the INHALE-1 Phase 3 trial for Afrezza in pediatrics and an adaptive Phase 2/3 study for inhaled clofazimine.

MannKind Corporation reported a net loss of $14.4 million for the third quarter of 2022, compared to a net loss of $4.4 million for the third quarter of 2021. Total revenues for the third quarter of 2022 were $32.8 million, an increase of 48% compared to the third quarter of 2021. The increase in total revenues was driven by an increase in collaborations and services revenue and an increase in commercial product sales.

MannKind Corporation reported total revenues of $18.9 million for the second quarter of 2022. This includes Afrezza net revenue of $10.6 million, V-Go net revenue of $2.1 million, collaborations and services revenue of $5.9 million, and royalties of $0.3 million. The net loss for the quarter was $29.0 million, or $0.11 per share.

MannKind Corporation reported total revenues of $12.0 million for the first quarter of 2022, with Afrezza net revenue increasing by 21% compared to the first quarter of 2021. The net loss for the quarter was $26.0 million, or $0.10 per share.

MannKind Corporation reported a solid fourth quarter with Afrezza net revenue hitting a record $11.3 million, and the company ended the year with over $260 million in cash and investments. Total revenues were $12.5 million, with Afrezza net revenue contributing $11.3 million and collaborations and services revenue contributing $1.2 million. The net loss for the quarter was $28.1 million, or $0.11 per share.

MannKind Corporation reported a total revenue of $22.2 million for Q3 2021, a 45% increase compared to Q3 2020. Afrezza net revenue increased by 34% to $9.8 million, and collaboration and services revenue increased by 54% to $12.5 million. The net loss for the quarter was $4.4 million, or $0.02 per share, compared to $11.3 million in Q3 2020.

MannKind Corporation reported a net loss of $35.5 million, or $0.14 per share, for the second quarter of 2021. Total revenues were $23.3 million, a 54% increase compared to the second quarter of 2020, driven by Afrezza net revenue of $10.0 million and collaboration and services revenue of $13.3 million. The company had $201.4 million in cash, cash equivalents and investments as of June 30, 2021.

MannKind Corporation reported a 7% increase in total revenues for Q1 2021, reaching $17.4 million, driven by growth in Afrezza net revenue and collaboration and services revenue. The company strengthened its financial position with $230 million in gross proceeds from senior convertible notes.

MannKind Corporation reported financial results for the fourth quarter and full year ended December 31, 2020. The company's Q4 total revenues were $18.4 million, including Afrezza net revenue of $10.1 million and collaborations and services revenue of $8.4 million. They also acquired QrumPharma Inc. for $12.8 million and entered into an agreement to co-promote Thyquidity beginning in Q1 2021.

MannKind Corporation reported financial results for the third quarter ended September 30, 2020. Total revenues were $15.4 million, with Afrezza U.S. net revenue reaching $7.3 million, a 27% increase compared to the same quarter in the previous year. The net loss for the quarter was $11.3 million, or $0.05 per share.

MannKind Corporation reported a net revenue of $15.1 million for Q2 2020, with Afrezza net revenue increasing by 15% compared to Q2 2019. The company's net loss decreased to $10.3 million, or $0.05 per share, compared to a $12.4 million net loss, or $0.07 per share, in the same period of 2019.

MannKind Corporation reported a net loss of $9.3 million for the first quarter of 2020, with Afrezza net revenue reaching $8.0 million, a 58% increase compared to the same quarter in 2019. The company's gross margin increased to 48%, driven by higher Afrezza revenue.

MannKind Corporation's Q4 2019 total revenues reached $16.0 million, with Afrezza net revenue at $7.8 million, a 35% increase compared to Q4 2018. The company's net loss for the quarter was $14.3 million, or $0.07 per share. The collaboration with United Therapeutics on TreT continues to make progress.